Stock VSTM VERASTEM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Verastem, Inc.

Equities

VSTM

US92337C2035

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
13.16 USD +9.48% Intraday chart for Verastem, Inc. +15.24% +61.67%
05-09 Verastem, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-18 Verastem Names John Hayslip as Chief Medical Officer MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Verastem, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Verastem, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Verastem Oncology's Ovarian Cancer Drug Gets FDA Orphan Drug Designation
DJ
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers
CI
Verastem Gets Fast Track Label For Avutometinib Combination in Non-Small Cell Lung Cancer
MT
Verastem Gets FDA Fast-Track Approval on Lung Cancer Treatment
DJ
Verastem Oncology Selects Oral Kras G12d Inhibitor Gfh375/Vs-7375 as Lead Program in Discovery and Development Collaboration with Genfleet Therapeutics
CI
Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
CI
Verastem Oncology Announces the Launch of the New Healthcare Professional Component
CI
Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS? in KRAS G12C-Mutant Non-Small Cell Lung Cancer
CI
Verastem Partners With GenFleet Therapeutics to Advance Oncology Discovery Programs
MT
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting Ras Pathway-Driven Cancers
CI
Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
CI
Reverse Split: 1 of 12
FA
Verastem, Inc. Announces an Update from Its International Phase 2 Ramp201 Trial Evaluating Avutometinib Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
CI
Verastem, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Verastem Oncology, Inc. Announces New Data from Interim Analysis of RamP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to Be Presented at the American Society of Clinical Oncology Annual Meeting
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VSTM Stock
  4. News Verastem, Inc.
  5. Highlights